Overview

Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection

Status:
Completed

Trial end date:
2011-05-01

Target enrollment:

Participant gender:

Summary

This study will analyse the dose-dependent effect of olmesartan medoxomil on the change in arterial stiffness in subjects with hypertension and metabolic syndrome

Phase:

Phase 3

Details

Lead Sponsor:

Daiichi Sankyo Europe, GmbH
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Treatments:

Olmesartan
Olmesartan Medoxomil